University of Victoria Global Survey Reveals Traumatic Brain Injury Survivors Turn to Psychedelics for Symptom Relief

University of Victoria study finds 90% of TBI survivors using psychedelics report symptom relief, highlighting a trend in self-medication for brain trauma.

By: AXL Media

Published: Apr 28, 2026, 6:03 AM EDT

Source: Information for this report was sourced from University of Victoria

Exploration of Alternative Therapies for Chronic Brain Trauma

Traumatic brain injuries affect approximately 60 million people globally every year, often leaving survivors with a complex array of cognitive, emotional, and physical challenges. Traditional medical treatments frequently fail to provide comprehensive relief, leading a growing number of patients to seek alternative supports. A new study co-authored by clinical psychology professors Jill Robinson and Mauricio Garcia-Barrera at the University of Victoria has identified a significant trend in the self-administration of psychedelic substances among this demographic. The researchers analyzed over 6,100 responses from the Global Psychedelic Survey, marking the first time human self-reports have been used to quantify the intersection of psychedelic use and brain injury recovery.

Patterns of Usage and Substance Selection

The data indicated that roughly 3.4% of the total survey sample, or 208 participants, were specifically using psychedelics to manage symptoms related to brain trauma. Among these individuals, psilocybin emerged as the most common substance of choice, typically administered in a mix of microdoses and larger doses every two to six months. Other respondents reported experimenting with LSD and ketamine to address their conditions. According to lead author Baeleigh VanderZwaag, the discovery that so many people are independently acquiring and testing these substances was unexpected, as the field of psychedelic research for TBI has historically been limited to animal models.

Perceived Efficacy and Symptom Improvement

While the study relies on self-reported data rather than clinical observation, the results suggest a high level of patient satisfaction. Approximately 90% of the participants who used psychedelics for TBI-related symptoms reported some degree of improvement in their quality of life. Survivors specifically noted relief from somatic symptoms, such as chronic headaches, as well as enhancements in mood and cognitive clarity. Professor Garcia-Barrera emphasized that because there is no "one size fits all" treatment for brain injury, these findings highlight a critical area where patients feel current medical standards are falling short, prompting them to experiment with unregulated substances.